Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

175
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
175
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

125
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
125
Hazard Ratio01:12

Hazard Ratio

110
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
110
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

123
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
123
Testing a Claim about Population Proportion01:24

Testing a Claim about Population Proportion

3.3K
A complete procedure for testing a claim about a population proportion is provided here.
There are two methods of testing a claim about a population proportion: (1) Using the sample proportion from the data where a binomial distribution is approximated to the normal distribution and (2) Using the binomial probabilities calculated from the data.
The first method uses normal distribution as an approximation to the binomial distribution. The requirements are as follows: sample size is large...
3.3K
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

121
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
121

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Impact of incretin therapies on biochemical and imaging outcomes in metabolic dysfunction-associated steatotic liver disease.

American journal of preventive cardiology·2026
Same author

Characteristics of Crowdfunding Campaigns for Proton Therapy.

International journal of radiation oncology, biology, physics·2026
Same author

TRIPLETE But Incomplete? Accounting for Post-Progression Therapy When Interpreting Overall Survival.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Nonparametric estimation of the total treatment effect with multiple outcomes in the presence of terminal events.

Biometrics·2026
Same author

Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

A versatile multi-components mixed model for bacterial-Genome Wide association studies.

Nature communications·2026

相关实验视频

Updated: Jun 21, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

484

贝叶斯中间分析和第三期随机试验的效率.

Alexander D Sherry, Pavlos Msaouel, Avital M Miller

    medRxiv : the preprint server for health sciences
    |July 9, 2024
    PubMed
    概括

    贝叶斯早期停止规则通过减少患者招募和成本,显著提高了III期瘤学试验的效率. 这种方法保留了试验解释,同时加快了有效疗法的批准.

    更多相关视频

    A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
    00:04

    A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

    Published on: September 20, 2019

    10.6K
    Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
    09:32

    Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

    Published on: February 8, 2018

    14.6K

    相关实验视频

    Last Updated: Jun 21, 2025

    Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
    08:36

    Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

    Published on: April 19, 2024

    484
    A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
    00:04

    A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

    Published on: September 20, 2019

    10.6K
    Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
    09:32

    Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

    Published on: February 8, 2018

    14.6K

    科学领域:

    • 临床试验方法论 临床试验方法论
    • 生物统计学 生物统计学
    • 瘤学研究研究

    背景情况:

    • 提高III期试验的效率对于降低成本和加速新疗法的批准至关重要.
    • 当前的临时评估方法可能无法完全优化试验效率或患者益处.
    • 贝叶斯统计方法为临床试验中早期停止规则提供了一个潜在的替代方案.

    研究的目的:

    • 评估该假设,即贝叶斯早期停止规则 in silico 提高了第三阶段瘤学试验的效率.
    • 为了比较贝叶斯早期停止规则与原始频率分析的效率.
    • 评估贝叶斯规则是否会损害对试验结果的整体解释.

    主要方法:

    • 对230个随机的III期瘤学试验 (184,752名参与者) 的横截面分析.
    • 从卡普兰-梅尔曲线重建了个别患者级数据.
    • 模拟试验积累 (每次试验100次) 使用已公布的结果,只改变积累动态.

    主要成果:

    • 贝叶斯早期停止标准在54%的模拟中得到满足.
    • 贝叶斯中间分析表明,试验结果的预测准确度很高 (AUC,0.91).
    • 贝叶斯规则将患者招募量减少了约11% (20,543名患者),并节省了估计8.51亿美元.

    结论:

    • 贝叶斯临时分析可以通过减少招生需求而提高随机试验效率,而不会影响解释.
    • 增加贝叶斯中间分析的利用,可以降低后期试验成本,加快有效治疗的批准.
    • 这种方法减轻了患者暴露于不利的随机化,并加速了有效治疗的可用性.